Today's Daily Dose brings you news about encouraging results of Cassava's Alzheimer's trial; FDA approval of DURECT's post-operative pain relief depot product, Posimir, Immunovant pausing IMVT-1401 trials and Travere's pivotal study of Sparsentan in focal segmental glomerulosclerosis yielding positive results.
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe -
- License Agreement with 3D ...